MiMedx Group (MDXG) has wrapped up FY 2025 with fourth quarter revenue of about US$118.1 million and basic EPS of roughly US$0.10, while trailing twelve month figures sit at around US$418.6 million of revenue and US$0.33 of basic EPS. Over the past few quarters, the company has seen revenue move from US$84.1 million in Q3 2024 to US$92.9 million in Q4 2024 and then to US$118.1 million in Q4 2025, with quarterly basic EPS ranging from about US$0.05 to US$0.11 across that stretch. With a trailing net profit margin of 11.6%, the latest earnings print gives investors a clear view of a business that is currently generating consistent profits.

See our full analysis for MiMedx Group.

With the headline numbers on the table, the next step is to see how this earnings story lines up against the widely followed narratives around MiMedx's growth, profitability, and longer term potential.

TTM profit of US$48.6 million supports 11.6% margin story

• Over the last twelve months to Q4 2025, MiMedx generated about US$418.6 million of revenue and US$48.6 million of net income, which lines up with the 11.6% net margin mentioned earlier and shows profit has stayed in the low double digits.
• Analysts' consensus view links this kind of profitability to long term earnings potential, yet the small move in net margin from about 12% to 11.6% shows that while the business is currently earning solid profits, it is not breaking away from margin pressure as clearly as the consensus narrative suggests.

Quarterly EPS range of US$0.05 to US$0.11 keeps growth grounded

• Across the last six reported quarters, basic EPS has sat in a fairly tight band between roughly US$0.05 and US$0.11 per share, with Q4 2025 at about US$0.10 and trailing twelve month EPS at about US$0.33, which shows earnings are positive but not moving in a straight line.
• Supporters in the bullish camp point to strong clinical positioning and product expansion as drivers of long term earnings, yet the step up and down in quarterly EPS within this US$0.05 to US$0.11 range reminds you that even with those tailwinds, the earnings path has been bumpy rather than smooth so far.
  • The bullish narrative highlights diversified product expansion and operational efficiencies as reasons to expect stronger earnings over time, while the actual EPS path from about US$0.05 in Q1 2025 to roughly US$0.11 in Q3 2025 and US$0.10 in Q4 2025 shows that cost and revenue timing still matter a lot quarter to quarter.
  • Backers also argue that investments in clinical trials and new launches can support margin improvement, but with trailing twelve month net income of around US$48.6 million on US$418.6 million of revenue, the current earnings base is still modest compared with the growth ambitions in that bullish story.

Bulls argue there is more to this EPS trend than the last few quarters show, and if you want to see how they frame the upside case in detail you can check out 🐂 MiMedx Group Bull Case

P/E of 15.1x vs slower 3.8% revenue forecast

• MiMedx is reported on a trailing P/E of 15.1x compared with a DCF fair value of US$14.55 per share and a current share price of US$4.94, while revenue growth is projected at about 3.8% per year, which is slower than the 10.4% figure cited for the broader US market.
• Critics in the bearish narrative focus on reimbursement changes and a concentrated product set as reasons that growth could be pressured, and the combination of a 3.8% revenue growth forecast and a net margin close to 11.6% gives those worries some footing even though the current P/E is lower than the 23x industry average.
  • The bearish view highlights potential Medicare reforms and possible market contraction as threats to both volumes and margins, and the already slower projected top line growth compared with the broader market shows why those policy shifts matter for future revenue lines.
  • Concerns about reliance on a limited placental allograft portfolio also tie back to the 11.6% net margin, because if reimbursement or competing products affect that core segment, the current earnings level of roughly US$48.6 million on US$418.6 million of sales could be sensitive to any shock in that main business.

Skeptics watching that 15.1x P/E against slower projected growth may want to see how a more cautious case is laid out in full through 🐻 MiMedx Group Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for MiMedx Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of bullish and cautious views here feels balanced, it is a good moment to look at the numbers yourself and move quickly to form your own stance, starting with 5 key rewards.

See What Else Is Out There

MiMedx's slower projected 3.8% revenue growth, modest EPS range, and sensitivity to reimbursement and product concentration leave plenty of questions about long term upside.

If those growth and concentration pressures give you pause, it may be a good time to widen the lens and review 53 high quality undervalued stocks, where the focus is on finding companies whose current pricing already reflects more conservative expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.